SOURCE: BioTech Medics, Inc.

BioTech Medics, Inc.

August 04, 2009 13:28 ET

BioTech Medics, Inc. Featured at Fat Cat Club Quarterly Meeting in Las Vegas

LAS VEGAS, NV--(Marketwire - August 4, 2009) - BioTech Medics, Inc. (PINKSHEETS: BMCS) announces Keith Houser, Chairman/CEO, will be presenting at the Quarterly Fat Cat Club Meeting at the Bellagio in Las Vegas on Thursday, August 13, 2009.

The Fat Cat Club is a national accredited investor angle network that meets quarterly to review investment opportunities. Membership is free to highly accredited investors; however guest attendees will be required to pay a one-time $99.00 fee for the Bellagio meeting and luncheon at Noon.

BioTech Medics, Inc. is a 12-year-old Nevada corporation that owns, operates and/or has affiliated Pain Management & Wellness Centers utilizing high powered deep penetrating FDA 510(k) cleared therapeutic medical lasers that reduce or eliminate muscle, nerve, skeletal and/or arthritic pain.

Frank Spady, Founder/CEO of Self-Directed Alliance of Las Vegas, will also be presenting with BioTech Medics on how you can self-direct 401(k), IRA and even Health Savings Accounts in BioTech. Mr. Spady was formerly CEO of Provident Group, a trust with over 8,000 clients. He previously worked as a Sr. VP of Sales with Boeing Computers and was the Exec. Director of the Nevada Association of Mortgage Brokers.

"If you are an accredited investor or one who has been laid off, a doctor, chiropractor, spa owner, displaced automobile dealer or a person with management experience wanting to make a change in your life, plan on attending this informative presentation," said Mr. Spady.

BioTech also has 4 US Letters of Patent for SHBAN™ Antimicrobial Hand Sanitizer that has been clinically proven to kill the Avian Bird Flu and is currently being tested to prove SHBAN's efficacy in killing the H1N1 (Swine) Influenza A. SHBAN does not contain alcohol and is 98% organic and biodegradable without harming humans or animals.

Safe Harbor: Forward-Looking Statements

This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). This is not an offer to buy or sell any security in any jurisdiction. Any offering or solicitation will be made only to qualified prospective investors pursuant to a confidential offering memorandum, and the subscription documents. The statements above have not been evaluated by the FDA. SHBAN is not intended to diagnose, treat or cure any disease.

Contact Information